With precious few buyouts in the Oncolytic space, Acuity has no doubt concluded as many here have that the BioVex deal at a structured one billion is likely the floor on this. So then, just how "Risky" is the apparently imprudent position Acuity has taken here...to the tune of some fifteen million shares? One can well imagine that the way this has been patiently and skillfully worked that a cost of less than three dollars is likely! So the team that is responsible for this has something like forty-five million of other peoples money at risk...with a calculated minimum upside expectation of over twelve dollars/share or $187,000,000...Now imagine three billion or even the outer limits of eleven billion! I think this Team is going after the trade of a lifetime and early retirement...Think BONUS!!!